CD23-mediated immunotherapy on airway inflammation
CD23介导的气道炎症免疫治疗
基本信息
- 批准号:8358273
- 负责人:
- 金额:$ 22.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAdultAdverse effectsAffinityAirAllergensAllergicAllergic DiseaseAllergic inflammationAllergic rhinitisAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAntigen-Presenting CellsApicalAsthmaBasophilsBindingBiotinBreathingBronchodilator AgentsBronchus-Associated Lymphoid TissueCD28 geneCD80 geneCTLA4-IgCell LineCell physiologyCellsChimeric ProteinsChronic Obstructive Airway DiseaseCytotoxic T-Lymphocyte-Associated Protein 4Dendritic CellsDevelopmentDiffusionDiseaseEffector CellEndocytic VesicleEndocytosisEpithelialEpithelial CellsEpitheliumExposure toExtrinsic asthmaFc ImmunoglobulinsFc ReceptorFunctional disorderFutureHistopathologyHumanHypersensitivityIgEIgE ReceptorsImmuneImmune responseImmunosuppressionImmunotherapeutic agentImmunotherapyInfantInflammationInflammatoryInflammatory ResponseKnockout MiceLabelLeadLectinLeukotrienesLiquid substanceLungLymphocyteMediatingMembraneModelingMusOvalbuminPathway interactionsPatientsPersonsPharmaceutical PreparationsPhasePhysiologicalProteinsRecombinantsRespiratory SystemRespiratory tract structureRouteSerumSteroidsSurfaceT-Cell ActivationTh2 CellsTherapeutic InterventionTight JunctionsTimeTissuesairway inflammationairway obstructionallergic airway inflammationanti-IgEapical membranebasebasolateral membraneeffective therapyeosinophilhuman diseaseimprovedmacromoleculemanmast cellmonolayernovelprotein transportreceptorrespiratoryresponsetherapeutic proteintranscytosisuptake
项目摘要
DESCRIPTION (provided by applicant): Allergic airway inflammations, such as asthma, are an increasingly important disease caused by bronchial inflammation and characterized by bronchial hyper-responsiveness and intermittent airway obstruction with an underlying Th2 cell-biased inflammatory response in the airways. The disease is currently treated with bronchodilators or anti- inflammatory drugs such as corticosteroids, leukotriene modifiers, and anti-IgE therapy, etc. However, the current treatments are not curative and some patients do not respond well to intense anti-inflammatory therapies. Additionally, the use of long-term steroids may result in many undesired side effects. For this reason, novel and more effective intervening strategies are greatly needed and explored. Targeting of the functions of Th2 cells and their products have been proposed as an effective strategy for the development of potential stand-alone treatments for allergic asthma. The reduction or elimination of allergen-specific Th2 cells in early disease development is expected to reduce the consequences of repeated allergic inflammatory. Hence, efficient delivery of immunotherapeutic proteins into the airway tract could effectively and directly interfere with allergen-specific Th2 cell activation in its earliest phaseof function. However, the polarized epithelial monolayer lining the airway forms mucosal barrier which is impervious to macromolecule diffusion. This barrier poses a major difficulty for an efficient delivery of immunotherapeutic proteins to access and cross-talk with underlying immune effector cells, such as Th2 cells, in the airway. Our recent studies have shown that human CD23 receptor is functionally capable of transporting IgE antibody across human lung and bronchial epithelial cells. In this study, we further propose to examine the feasibility of CD2 to deliver the immunotherapeutic proteins, which are targeted to interfere with CD4 Th2 cell function, across airway mucosal barrier in a mouse allergy model. These studies, therefore, are very likely to lead to greatly improved novel therapies that protect against and potentially cure asthma and allergic diseases.
PUBLIC HEALTH RELEVANCE: CD23-mediated immunotherapy on airway inflammation Airway inflammation, asthma, is among the most common diseases in both infant and adult. CD23 is capable of transporting IgE across airway epithelial cells. This study will explore the feasibility whether CD23 can deliver an immunotherapeutic protein to modulate or dampen the development of airway allergic inflammation.
描述(由申请人提供):过敏性气道炎症,如哮喘,是由支气管炎症引起的日益重要的疾病,其特征在于支气管高反应性和间歇性气道阻塞,气道中存在潜在的Th2细胞偏向性炎症反应。目前使用支气管扩张剂或抗炎药物(如皮质类固醇、白三烯调节剂和抗IgE治疗等)治疗该疾病。然而,目前的治疗方法无法治愈,一些患者对强烈的抗炎治疗反应不佳。此外,长期使用类固醇可能会导致许多不希望的副作用。因此,迫切需要探索新的、更有效的干预策略。靶向Th2细胞及其产物的功能已被提出作为开发潜在的过敏性哮喘独立治疗的有效策略。在疾病发展早期减少或消除过敏原特异性Th2细胞预期可减少反复过敏性炎症的后果。因此,有效地将免疫调节蛋白递送到气道中可以有效地和直接地干扰变应原特异性Th2细胞在其功能的最早阶段的激活。然而,排列在气道内的极化的上皮单层形成粘膜屏障,其不受大分子扩散的影响。这种屏障对于有效递送免疫调节蛋白以接近气道中的潜在免疫效应细胞(例如Th2细胞)并与之交叉作用造成了主要困难。我们最近的研究表明,人CD23受体在功能上能够转运IgE抗体穿过人肺和支气管上皮细胞。在这项研究中,我们进一步提出了研究的可行性,CD2提供免疫调节蛋白,这是有针对性的干扰CD4 Th2细胞功能,通过气道粘膜屏障在小鼠过敏模型。因此,这些研究很有可能导致大大改进的新疗法,从而预防和潜在地治愈哮喘和过敏性疾病。
公共卫生相关性:CD23介导的气道炎症免疫治疗气道炎症,哮喘,是婴儿和成人最常见的疾病之一。CD23能够跨气道上皮细胞转运IgE。本研究将探讨CD23是否可以传递免疫调节蛋白来调节或抑制气道过敏性炎症的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIAOPING ZHU其他文献
XIAOPING ZHU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIAOPING ZHU', 18)}}的其他基金
FcRn-Targeted Mucosal Vaccination Against Influenza Infections
针对流感感染的 FcRn 靶向粘膜疫苗接种
- 批准号:
10397578 - 财政年份:2019
- 资助金额:
$ 22.8万 - 项目类别:
FcRn-Targeted Mucosal Vaccination Against Influenza Infections
针对流感感染的 FcRn 靶向粘膜疫苗接种
- 批准号:
10599875 - 财政年份:2019
- 资助金额:
$ 22.8万 - 项目类别:
CD23-mediated immunotherapy on airway inflammation
CD23介导的气道炎症免疫治疗
- 批准号:
8499250 - 财政年份:2012
- 资助金额:
$ 22.8万 - 项目类别:
AIDS Vaccine Strategy Using IgG Transfer Pathway
使用 IgG 转移途径的艾滋病疫苗策略
- 批准号:
7230380 - 财政年份:2007
- 资助金额:
$ 22.8万 - 项目类别:
AIDS Vaccine Strategy Using IgG Transfer Pathway
使用 IgG 转移途径的艾滋病疫苗策略
- 批准号:
7458667 - 财政年份:2007
- 资助金额:
$ 22.8万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 22.8万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 22.8万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 22.8万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 22.8万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 22.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 22.8万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 22.8万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 22.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 22.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 22.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)